Search

Displaying results 3901 - 3910 of 8469 in total
  1. Drug

    Human umbilical cord blood mononuclear cell-conditioned medium

    go.drugbank.com/drugs/DB15724
    Experimental

    Transplantation with human umbilical cord blood mononuclear cells (HUCBC) has demonstrated promising results in various disease states.

  2. Drug

    Mandelic acid

    go.drugbank.com/drugs/DB13218
    Approved

    Mandelic acid is used as an ingredient in cosmetics and drug products applied topically.

  3. Drug

    Diflorasone

    go.drugbank.com/drugs/DB00223
    Approved

    Diflorasone is a topical corticosteroid used to treat itching and inflammation of the skin.

  4. Drug

    Eflepedocokin alfa

    go.drugbank.com/drugs/DB16366
    Investigational

    [A225706, L27661] It is being developed by Evive Biotech (previously known as Generon BioMed Inc).[L27666]

  5. Drug

    Diethylcarbamazine

    go.drugbank.com/drugs/DB00711
    ApprovedInvestigationalVet approvedWithdrawn

    An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.

  6. Drug

    Secobarbital

    go.drugbank.com/drugs/DB00418
    ApprovedVet approved

    It is commonly known as quinalbarbitone in the United Kingdom.

  7. Drug

    NRP409

    go.drugbank.com/drugs/DB05235
    Experimental

    NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.

  8. Drug

    SR-123781A

    go.drugbank.com/drugs/DB05361
    Investigational

    SR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).

  9. Drug

    Garetosmab

    go.drugbank.com/drugs/DB16379
    ApprovedInvestigational

    [L63940] Garetosmab-grts was approved by the FDA on August 19, 2026 to reduce the number of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP. … [L63940,L64047] It is the second therapy approved for FOP, following [palovarotene] (Sohonos), which was approved in 2023, and is the first FOP therapy shown to reduce clinician-assessed flare-ups.

  10. Drug

    Tinidazole

    go.drugbank.com/drugs/DB00911
    ApprovedInvestigational

    A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.